Disease burden and clinical severity of the first pandemic wave of COVID-19 in

2 Wuhan, China

1

3

7

10

- 4 Juan Yang, PhD ^{1#}, Xinhua Chen, BSc ^{1#}, Xiaowei Deng, MSc ¹, Zhiyuan Chen, BSc ¹,
- 5 Hui Gong, BSc ¹, Han Yan, BSc ¹, Qianhui Wu, BSc ¹, Huilin Shi, BSc ¹, Shengjie
- 6 Lai, PhD ^{1,2}, Marco Ajelli, PhD³, Cecile Viboud, PhD⁴, Prof Hongjie Yu, PhD¹
- 8 *These authors contributed equally to this work.
- 9 Corresponding author to Prof. Hongjie Yu, yhj@fudan.edu.cn
- 11 **Affiliations:**
- 12 1. School of Public Health, Fudan University, Key Laboratory of Public Health
- 13 Safety, Ministry of Education, Shanghai, China
- 14 2. WorldPop, Department of Geography and Environment, University of
- 15 Southampton, University Road, Southampton, SO17 1BJ, UK
- 16 3. Department of Epidemiology and Biostatistics, Indiana University School of Public
- 17 Health, Bloomington, IN, USA
- 4. Division of International Epidemiology and Population Studies, Fogarty
- 19 International Center, National Institutes of Health, Bethesda, MD, USA

²⁰ NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

ertified by peer	review) is the author/funder, who has g	grantea meakxiv a	a license to disp	play the prepi
	perpetuity.			
It is made a	available under a CC-BY-NC-ND 4 0 Inte	arnational license		

- 21 This study does not necessarily represent the views of the US government or the
- 22 National Institutes of Health.
- 24 Word count (abstract): 148

- 25 Word count (main text):3,720
- Running head: Disease burden and clinical severity of COVID-19 in Wuhan 26

Abstract

The pandemic of novel coronavirus disease 2019 (COVID-19) began in Wuhan, China, where a first wave of intense community transmission was cut short by interventions. Using multiple data source, we estimated the disease burden and clinical severity of COVID-19 by age in Wuhan from December 1, 2019 to March 31, 2020. We adjusted estimates for sensitivity of laboratory assays and accounted for prospective community screenings and healthcare seeking behaviors. Rates of symptomatic cases, medical consultations, hospitalizations and deaths were estimated at 796 (95%CI: 703-977), 489 (472-509), 370 (358-384), and 36.2 (35.0-37.3) per 100,000 persons, respectively. The COVID-19 outbreak in Wuhan had higher burden than the 2009 influenza pandemic or seasonal influenza, and that clinical severity was similar to that of the 1918 influenza pandemic. Our comparison puts the COVID-19 pandemic into context and could be helpful to guide intervention strategies and preparedness for the potential resurgence of COVID-19.

Introduction

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

As of 26 July 2020, 188 countries have been affected by the novel coronavirus disease 2019 (COVID-19), with 15,745,102 COVID-19 cases and 644,661 deaths reported worldwide¹. COVID-19 has a broad spectrum of severity. The bottom of the severity pyramid includes serological-confirmed infections, of which only a fraction will develop symptoms. A fraction of symptomatic cases may seek medical care, when they can be identified via surveillance systems, require hospitalization and die. Hospitalization is an important metric as it determines the strain exerted by an epidemic on the health care system. Further, deaths are highly relevant to planning pandemic response, as mortality is an outcome that health authorities typically aim to minimize. (Fig.1a) Estimates of disease burden and clinical severity of COVID-19 are critical to identify appropriate intervention strategies, plan for healthcare needs, and ensure the sustainability of the health system throughout the duration of the pandemic. However, quantifying these estimates based on surveillance data is challenging due to changes in health seeking behaviors during the pandemic, as well as underdiagnoses. For instance, the detection of a novel pathogen may give a high rate of false negatives. Historically, two influenza pandemics had far-reaching influence to humankind worldwide: the 1918 and 2009 influenza pandemics². The 1918 influenza pandemic is

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

typically considered as the worst-case pandemic scenario for pandemic planning. In contrast, the 2009 influenza pandemic is considered mild but provides a benchmark for a pandemic in modern times, as the health systems, supportive care, and populations, are comparable with those of today. Comparing the COVID-19 burden and clinical severity with past influenza pandemics can help public health officials interpret the magnitude of the COVID-19 pandemic and the success of the response efforts. A further comparison between the COVID-19 pandemic and seasonal influenza can be useful to optimize health resource allocations, considering their overlapping circulation periods. Wuhan is a particularly well-suited location to assess the health burden of COVID-19. Firstly, Wuhan experienced intense community transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); secondly, the first wave has ended, with only seven sporadic cases reported between March 24 and May 18³. Therefore, the first epidemic wave in Wuhan (for the period December 1, 2019-March 31, 2020) is an opportunity to comprehensively quantify the disease burden and clinical severity of COVID-19. Here we used multiple data sources to estimate agespecific rates of symptomatic SARS-CoV-2 infections, medically attended cases, hospitalizations, and deaths, accounting for health seeking behaviors and underdiagnoses. We also estimated rates of medically attended influenza-like-illness (ILI) associated with SARS-CoV-2 infections; hospitalizations with severe acute

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

respiratory infection (SARI), and pneumonia hospitalizations associated with SARS-CoV-2 infections by dividing the number of ILI consultations, SARI hospitalizations and pneumonia hospitalizations by the number of symptomatic SARS-CoV-2 infections. Moreover, we estimated the clinical severity of COVID-19 including the symptomatic case-fatality risk (sCFR), medically attended case-fatality risk (mCFR), hospitalization-fatality risk (HFR), symptomatic case-hospitalization risk (sCHR), and medically attended case-hospitalization risk (mCHR). The rates of symptomatic cases, medically attended cases, hospitalizations, and deaths with SARS-CoV-2 were calculated by dividing the number of cases at each level of severity by population size. Clinical severity was obtained by dividing the numbers of cases in the corresponding severity pyramid. (Fig. 1a) Finally, we compared our estimates with those of the 1918 and 2009 influenza pandemics, and with seasonal influenza. **Results Reported COVID-19 cases** We obtained the number of laboratory-confirmed COVID-19 cases and clinicallydiagnosed cases in Wuhan from published literature and the Hubei Health Commission^{3, 4}. Cases were mainly confirmed by real-time reverse transcription polymerase chain reaction (RT-PCR) and included mild, moderate, severe, and critical cases^{5, 6, 7, 8}. Mild cases refer to cases with mild symptoms and no radiographic evidence of pneumonia. Moderate cases refer to cases with fever, respiratory

symptoms, and radiographic evidence of pneumonia. Severe cases refer to cases with any breathing problems, finger oxygen saturation, and low PaO2/FiO2 (PaO2 denotes partial pressure of oxygen in arterial blood; FiO2 denotes fraction of inspired oxygen), etc. Critical cases refer to cases having any respiratory failure, shock, and any other organ failure that requires ICU admission. Clinically-diagnosed cases included suspected cases with pneumonia as indicated by chest radiography, but without virological confirmation of infection⁶. (Supplementary Information File 1) These clinically-diagnosed cases were included in our study, recognizing the value of a clinical definition at the peak of a pandemic and in the context of limited laboratory testing capacity. A total of 50,333 COVID-19 cases were reported in the four-month epidemic in Wuhan. Of them, 32,968 (65.5 %) were laboratory-confirmed cases. As of July 20, 3,869 cases have died, and all others recovered. These cases were recorded from passive surveillance which was launched at the start of the outbreak in late December 2019 in Wuhan⁹, and from active door-to-door and individual-to-individual screenings for fever (Supplementary Information File 2) 10, 11.

Estimated disease burden of COVID-19

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

RT-PCR sensitivity for SARS-CoV-2 detection varies based on the interval between symptom onset and laboratory testing, which was highest (97.9%) at an interval of <7 days¹². A population-based telephone and online survey conducted in Wuhan found that 35.4% (95%CI 28.4%-43.9%) of patients with acute respiratory infections (i.e.,

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

fever with any symptoms of cough, and/or sore throat) sought medical care during the epidemic of COVID-19¹³. All cases from passive surveillance were considered as medically attended cases. In the baseline analysis, we assumed that a proportion of mild cases, and all moderate-to-critical cases (had radiographic evidence of pneumonia) captured by active screening in the community would eventually seek medical care given that the health system was not overwhelmed. It was assumed that the cases from passive surveillance had the same health seeking behavior as those captured by active screening in the community. Laboratory-confirmed cases (moderate-to-critical) and clinically-diagnosed cases had radiographic evidence of pneumonia, and thus were considered as requiring hospitalization. (Fig. 1b) After adjusting for sensitivity of RT-PCR testing, and accounting for the probability of seeking medical care and prospective screening in the community, we estimated that a total of 52,300 (95%CI 50,500-54,500) medically-attended cases and 39,600 (95%CI 38,300-41,100) hospitalizations were associated with COVID-19. In Wuhan, over the period from December 2019 to March 2020, the rates of symptomatic cases, medical consultations, hospitalizations and deaths for COVID-19 were 796 (95%CI 703-977), 489 (95% CI 472-509), 370 (95% CI 358-384) and 36.2 (95% CI 35.0-37.3) per 100,000 individuals respectively. A consistent increasing trend with age was observed across all metrics, with the highest rates occurring in adults aged 60 years and over (Fig.2a, Fig.3a, Fig.4a and Supplementary Information File 3).

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

The rate of medical consultation for COVID-19 (mean: 489 per 100,000 individuals) was lower than that of the 2009 influenza pandemic in China and the US (680 and 1,030 per 100,000 individuals, respectively). The rate of medical consultation was intermediate between that of the 2012-2013 influenza season in the US (1,070 per 100,000 persons) and the 2006-2015 influenza seasons in China (mean: 250 per 100,000 individuals per year) 14, 15. (Fig. 2a-2e and Supplementary Information File 3-4) The hospitalization rates of COVID-19 in Wuhan were 3.1-fold higher than that of the 2009 influenza pandemic, and 1.8-2.6 times that of seasonal influenza^{16, 17, 18, 19}. Higher hospitalization burden was found among older adults for COVID-19, while the hospital burden was shifted towards children for seasonal influenza in China²⁰ and the 2009 influenza pandemic in the US¹⁶. (Fig.3 and Supplementary Information File 3-4) The overall mortality rate of COVID-19 in Wuhan was much higher than that of 2009 influenza pandemic and seasonal influenza (36.2 vs. 3.6-6.5 per 100,000 individuals) ^{20, 21, 22}. (Fig.4 and Supplementary Information File 3-4) **Estimated clinical severity of COVID-19** The overall sCFR of COVID-19 was 4.54% (95%CI 3.70-5.14%), which is comparable, if not higher, than that of the 1918 influenza pandemic – from the

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

analysis of data from eight US localities, the sCFR was estimated at 1.61% and 1.98% for the first and second wave, respectively^{23, 24}. Such a figure is substantially higher than that of the 2009 influenza pandemic (<0.1% in the US) ²⁵. The sCFR of COVID-19 was higher for adults aged \geq 60 years than for the other age groups (9.09% vs. 0.36%-1.97%). (Fig.5a-5c and Supplementary Information File 5) In contrast, younger age groups were the most affected segment of the population during the 1918 and 2009 influenza pandemic, while both young and old individuals were the most affected during seasonal influenza epidemics^{14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26} The HFR (9.77%, 95%CI 9.41%-10.10%) and sCHR (46.48%, 95%CI: 39.33%-50.93%) were higher for COVID-19 than for the 2009 influenza pandemic (HFR: 2.6% in North America²⁶; sCHR: 1.44% in the US²⁵)(Fig.5e-5h and Supplementary Information File 5). Sensitivity analyses To assess the robustness of our findings, we conducted four sensitivity analyses: In scenario i) we assumed that moderate cases had the same health seeking behavior as mild cases, i.e., only a proportion of moderate cases sought medical assistance; in scenario ii) we excluded clinically-diagnosed cases; in scenario iii) we used the upper limit of 95% CI of the probability of seeking medical care; and in scenario iv) we used the lower limit of 95%CI of the probability of seeking medical care. Compared to the

baseline analysis, the mean rates of symptomatic cases for COVID-19 increased from 796 to 935 per 100,000 persons in scenario i) and 960 per 100,000 persons in scenario iv), while rates decreased to 634 per 100,000 persons in scenario ii) and 719 per 100,000 persons in scenario iii). The sCFR decreased from 4.54% to 3.87% in scenario i) and 3.77% in scenario iv), while it increased to 5.38% in scenario ii) and 5.03% in scenario iii). Similar patterns were observed for the other metrics of interests (Supplementary Information File 3). Overall, the estimated variations did not change our findings, particularly for comparison of COVID-19 with pandemic and seasonal influenza.

ILI consultations and SARI/pneumonia hospitalizations

We quantitatively assessed the impact of COVID-19 on the healthcare sector using the local number of ILI consultations and SARI/pneumonia hospitalizations in the absence of COVID-19 as a reference. The rate of medically attended COVID-19 was approximately 1.3 times the baseline ILI consultations among adults of \geq 60 years of age. The hospitalization rate of COVID-19 was 3-6 fold higher than baseline SARI hospitalizations among adults of \geq 20 years of age, and 25-132 fold higher than pneumonia hospitalizations as a reference (and Supplementary Information File 6).

Discussion

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

This study uses multiple sources of data to estimate different levels of the COVID-19 severity pyramid. We find that the mean rates of symptomatic cases, medical consultations, hospitalizations and deaths were respectively 796, 489, 370, and 36.2 per 100,000 persons in Wuhan from December 2019 to March 2020. All burden metrics increased with age, with adults ≥60 years of age most affected. Similarly, the highest sCFR and HFR were found in older adults. Our study is strengthened by adjustment for several potential biases. First, rates of medical consultations were adjusted by the sensitivity of RT-PCR assays¹². Sensitivity was only 30-40% before January 23 due to delayed detection, which could lead to important underdiagnoses and has not been considered in previous studies. Second, we accounted for the health seeking behaviors among the Wuhan population during the epidemic¹³. The probability of seeking medical treatment conditionally on symptoms of acute respiratory diseases is a critical parameter to estimate the true number of COVID-19 cases in community. Accordingly, our estimates of disease burden may be the most accurate for Wuhan so far. Two studies reported on COVID-19 disease burden in the US and Canada by the end of May, at which time local epidemics are still ongoing (Supplementary Information File 7) ^{27, 28}. The overall rate of symptomatic cases (796 vs. 404-534 per 100,000 persons) in Wuhan was much higher than that in the US and Québec, a severely

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

affected province of Canada. Variation in testing strategies likely contribute to the difference in rate of symptomatic cases, in addition to true difference in epidemic dynamics. Unlike in Wuhan, only individuals with signs or symptoms consistent with COVID-19, and asymptomatic individuals with suspected exposure were preferentially tested in the US. Moreover, in contrast to our study, the US and Canadian estimates were not adjusted for the sensitivity of RT-PCR assays and health seeking behavior, and thus may be underestimated. Our estimated hospitalization rate for a four-month COVID-19 outbreak was much higher than that for a three-to-six-month COVID-19 outbreak in the US and Québec (370 vs. 47-114 per 100,000 persons) ^{27, 28, 29, 30}. We estimated that 76% of medicallyattended cases were hospitalized in Wuhan, while only 18% were hospitalized in the US³⁰. The difference between these estimates could be explained by the potential different clinical thresholds for hospitalization. We assumed that moderately ill cases with radiographic evidence of pneumonia and more severe cases would be hospitalized in the context of medical practices in China, based on the probability of progression from disease to death³¹. However, such results may not apply to other countries with different healthcare practice and general health seeking behaviors. For example, Chinese patients are less likely to seek care at primary health institutions than hospitals³².

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

The mortality rate of COVID-19 in Wuhan was lower than the excess mortality in New York City (24,172 excess deaths³³ among 19,746,286 individuals, and thus 122 per 100,000 individuals), and Québec (52 per 100,000 persons)²⁸, but similar to the national excess all-cause mortality in the US (122,300 excess deaths among 332.382.720 individuals, and thus 36.8 per 100,000 individuals)³⁴. In our study, patients who died at home or died before being diagnosed were not considered, which could have been important in the early phase of the epidemic due to underascertainment. A recent comprehensive correction of official tallies of cases and deaths by the Wuhan Authorities, included in this study, could minimize this underascertainment. Further research should use excess mortality approaches³³ to capture the full burden of the outbreak, when vital registration data for this period become available. Our estimates of sCFR (4.54% vs. 1.2-1.4%) and mCFR (7.40% vs 5.91%) for Wuhan are higher than in prior modeling studies^{35, 36}. This is likely explained by the addition of revised statistics on cases and deaths, and a more complete dataset with no rightcensored outcomes in our study. Large variations in mCFR were observed between countries, which have not been systematically analyzed. Qualitatively, these variations could be explained by differences in the sensitivity of surveillance systems

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

to detect cases at different levels of the severity pyramid, differences in clinical care of severe and critical patients, and in age structure and underlying conditions of the population. Our HFR estimate (9.77%) is higher than the estimate obtained by Wang et al. in a highly censored sample in Wuhan in the very early stages of the epidemic $(4.3\%)^{37}$. However, it is much lower than the 28% estimate obtained in two COVID-19designated hospitals for severe COVID-19 cases in Wuhan, probably due to the particularly high proportion of severe and critical patients hospitalized in these facilities (64% vs. 28%)³⁸. Our HFR estimate was lower than the 18.1% estimate in France³⁹, probably due to aforementioned loose threshold for hospital admissions in China and preference of seeking care in hospitals rather than outpatient settings. We systematically compared the burden of the COVID-19 outbreak with that of the 1918 and 2009 influenza pandemics and seasonal influenza. Our COVID-19 estimates are substantially higher than those of the 2009 influenza pandemic and seasonal influenza, and similar to the 1918 influenza pandemic. However, the age pattern of severe disease was clearly different. Our COVID-19 severity estimates increased with age. In contrast, younger age groups were the most affected by 1918 and 2009 influenza pandemic, and both youngest and oldest individuals were the most affected by seasonal influenza. Small changes were observed when we adjusted the overall

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

burden and clinical severity of seasonal and pandemic influenza using Wuhan age profile as a reference (Supplementary Information File 5 and File 8). Comparison of severity estimates between pandemics was difficult to standardize, particularly for 1918 influenza pandemic²³. The 1918 sCFR is based on data from a single US study from more than a 100 years ago, at a time when awareness of viral diseases was inexistent, case ascertainment and disease surveillance were limited, and definition of clinical outcomes varied. Therefore, our comparison was not intended to quantify the absolute value of differences, but to put the COVID-19 pandemic into perspective. To put our results in perspective, it is important to stress that our COVID-19 estimates refer to the first epidemic wave in Wuhan - a four-month long period. The epidemic was controlled by intense interventions⁴. If the epidemic rebounds, as one would expect if the infection was reintroduced in a population with low immunity, the disease burden would rise. Moreover, given that the epidemic lasted only four months, the stress on the healthcare system was tremendous, as severe cases and hospitalizations were concentrated over a relatively short period of time. Furthermore, neither seasonal nor pandemic influenza outbreaks were controlled, as vaccination was either low or delayed until after the main wave had passed, and no social distancing was put in place.

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

Using a simple data-driven approach, we quantitatively assessed the impact of COVID-19 on the healthcare sector using the local number of ILI consultations and SARI/pneumonia hospitalizations in the absence of COVID-19 as a reference. The number of COVID-19 hospitalizations was several folds higher than that of baseline SARI hospitalizations and 25-132 folds higher than that of pneumonia hospitalizations among adults ≥ 20 years of age. This indicates that during this time period, the Wuhan healthcare system considerably exceeded surge capacity, highlighting the importance and necessity of preparedness for sufficient healthcare resources. Moreover, there is a winter peak of consultations and hospitalizations related to respiratory diseases such as seasonal influenza and respiratory syncytial virus^{14, 40, 41}, which may have contributed to overwhelm the healthcare sector during the first wave of the COVID-19 epidemic. Our study has some limitations. Firstly, health seeking behavior maybe not constant throughout the epidemic. In this survey, study participants in Wuhan were asked to review their history of ARI between December 2019 and March 2020, and whether they sought medical assistance for these symptoms¹³. However, since we did not obtain the onset date of these symptoms, and hence we could not stratify healthseeking behavior by COVID-19 epidemic phase. Instead, we calculated the overall proportion of ARIs cases who sought medical care during the epidemic. If the distribution of onset dates of ARIs cases in our sample was skewed towards the early

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

phase (late January) of the epidemic, the proportion seeking medical care may be underestimated due to the overwhelmed health system. That would lead to an overestimation of the number of symptomatic COVID-19 cases. Conversely, if the distribution of onset dates was skewed towards the late phases of epidemic, we may have underestimated the number of symptomatic COVID-19 cases. We conducted a sensitivity analysis on the probability of seeking medical care, using the lower and upper limits of the 95%CI of our survey. This analysis resulted in minor changes in the disease burden and clinical severity estimates compared to the baseline analysis. Secondly, missing or incorrect records of COVID-19 cases are inevitable during an outbreak, particularly in the period when the healthcare capacity is overwhelmed. A verification of reported COVID-19 cases was conducted by Wuhan Authorities to correct for late reporting, omissions and mis-reporting, with 325 laboratory-confirmed cases and 1,290 deaths added to official tallies. Due to the high specificity of RT-PCR assay (almost 100%), false positives were rare^{42, 43, 44, 45}. We included in the analysis clinically-diagnosed cases that were reported for a brief one-week period, when testing could not keep up, so we inevitably overestimated the true number of COVID-19 cases. Our sensitivity analyses showed that the exclusion of these clinicallydiagnosed cases led to decreased estimates of disease burden and increased estimates of clinical severity. However, our conclusions are robust to these changes. Moreover, while reporting of cases changed at the beginning of the pandemic as the definition of

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

COVID-19 suspected cases broadened to include a milder spectrum, we expect reporting was relatively stable throughout the rest of the outbreak although this would be difficult to prove conclusively. Additionally, it is difficult to extrapolate our findings to other countries/regions since estimates of clinical severity and disease burden of COVID-19 are influenced by multiple factors such as the evolution of the epidemic, intervention policies, case detection strategy, surge capacity of healthcare systems, differences in presentation, triage, and treatment, and health seeking behavior over time and across locations. A modelling study has revealed that containment has proved to be successful to control the local COVID-19 epidemic in Wuhan. Without containment efforts, the number of COVID-19 cases would have been an estimated 67-fold higher than that has been thus far⁴⁶. Therefore, our estimates in Wuhan could represent the disease burden and clinical severity in a region with 1) wide-spread community transmission of SARS-CoV-2; 2) strict non-pharmaceutical interventions, referred as to "wartime measures" in the study by Leung et al.⁴⁷; 3) extensive detection of all outpatients with fever¹⁰; 4) enhanced healthcare capacity. Indeed, Wuhan experienced remarkably rapid and extensive support from top-level medical staff drawn from all over China, as well as rapid establishment of medical facilities like the Leishenshan and Fangcang shelter hospitals^{48, 49, 50}. Although the COVID-19 pandemic has already spread across the world, and the scale of epidemics in western countries, like the US and Brazil,

374

375

376

377

378

379

380

381

382

383

384

385

386

387

exceeded that in Wuhan by far, the pandemic in other countries is still ongoing and any estimate is bound to be revised. Our estimates represent the full impact of a short but intense first wave, and could be considered as benchmarks to plan intervention strategies for a potential second wave of the pandemic. In the first wave of the COVID-19 pandemic from December 2019 through March 2020 in Wuhan, China, intense community transmission caused higher disease burden than the 2009 influenza pandemic and seasonal influenza. Overall, we find that the clinical severity of COVID-19 seems to be in the same order of magnitude as that of the 1918 influenza pandemic. In contrast to the age pattern of influenza virus infection, however, the highest burden and clinical severity of COVID-19 is observed among older adults, while children are less affected. During the epidemic of COVID-19, the Wuhan healthcare system considerably exceeded surge capacity. This study is helpful to guide intervention strategies and healthcare preparedness for the potential re-emergence of COVID-19 in China and beyond.

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

Figure legend Figure 1. Severity levels of COVID-19 and schematic diagram of the baseline analyses. A: Severity levels of infections with SARS-CoV-2 and parameters of interest. Each level is assumed to be a subset of the level below. sCFR: symptomatic case-fatality risk; sCHR: symptomatic case-hospitalization risk; mCFR: medically attended casefatality risk; mCHR: medically attended case-hospitalization risk; and HFR: hospitalization-fatality risk. B: Schematic diagram of the baseline analyses. Data source of COVID-19 cases in Wuhan: D1) 32,583 laboratory-confirmed COVID-19 cases as of March 8⁴, D2) 17,365 clinically-diagnosed COVID-19 cases during February 9-19⁴, D3)daily number of laboratory-confirmed cases on March 9-April 24³, D4) total number of COVID-19 deaths as of April 24 obtained from the Hubei Health Commission³, D5) 325 laboratory-confirmed cases and D6) 1,290 deaths were added as of April 16 through a comprehensive and systematic verification by Wuhan Authorities³, and D7) 16,781 laboratory-confirmed cases identified through universal screening 10,11 . P_{se} : RT-PCR sensitivity¹². $P_{med.care}$: proportion of seeking medical assistance among patients suffering from acute respiratory infections¹³. (Red, blue and green arrows

separately denote the data flow from laboratory-confirmed cases of passive

surveillance, clinically-diagnosed cases, and laboratory-confirmed cases of active screenings)

Figure 2. Rates of symptomatic cases and of medical consultation rates by age group (mean, 95%CI)

a: rates of medical consultation associated with COVID-19 in Wuhan, China

b: rates of medical consultation associated with 2009 pandemic H1N1 influenza,

China¹⁴

c: rates of medical consultation associated with 2009 pandemic H1N1 influenza,

USA¹⁵

d: seasonal influenza-associated excess ILI outpatient consultations rates, China¹⁴

e: rates of medical consultation associated with seasonal influenza, USA¹⁵

419 Figure 3. Hospitalization rates 420 a: rates of hospitalization associated with COVID-19 in Wuhan, China (mean, 421 95%CI) 422 b: rates of hospitalization associated with 2009 pandemic H1N1 influenza, USA (median, range)¹⁶ 423 424 c: rates of hospitalization associated with seasonal influenza related SARI in Jingzhou, Hubei province, China (median, range)¹⁷ 425 d: rates of hospitalization associated with seasonal influenza, USA (mean, 95%CI)¹⁸, 426 19 427

Figure 4. Mortality rates a: rates of mortality associated with COVID-19 in Wuhan, China (mean, 95%CI) b: rates of mortality associated with 2009 pandemic H1N1 influenza, USA (75% percentile)²⁰ c: excess mortality rates associated with seasonal influenza, China (mean, 95%CI)²¹ d: excess mortality rates associated with seasonal influenza, USA (median, 95% credibility interval)²²

428

429

430

431

432

433

434

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

Wuhan, China (mean, 95%CI)

Figure 5. Clinical severity a: symptomatic case-fatality risk (sCFR) associated with COVID-19 in Wuhan, China (mean, 95%CI) b: symptomatic case-fatality risk (sCFR) associated with 1918 pandemic H1N1 influenza in August - December 1918, USA (mean)²³ c: symptomatic case-fatality risk (sCFR) associated with 2009 pandemic H1N1 influenza, USA (median, 95% CI)²⁵ d: medically attended case-fatality risk (mCFR) associated with COVID-19 in Wuhan, China (mean, 95%CI) e: hospitalization-fatality risk (HFR) associated with COVID-19 in Wuhan, China (mean, 95%CI) f: hospitalization-fatality risk (HFR) associated with 2009 pandemic H1N1 influenza, North America (mean,95%CI)²⁶ g: symptomatic case-hospitalization risk (sCHR) associated with COVID-19 in Wuhan, China (mean, 95%CI) h: symptomatic case-hospitalization risk (sCHR) associated with 2009 pandemic H1N1 influenza, USA (median,95%CI)²⁵ i: medically attended case-hospitalization risk (mCHR) associated with COVID-19 in

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

Methods **Case definitions** Case definitions for laboratory-confirmed-cases were issued by the National Health Commission of China, and included mild, moderate, severe, and critical cases. Cases were confirmed by real-time reverse transcription polymerase chain reaction (RT-PCR) or by viral sequencing indicating genomes highly homologous to SARS-CoV-2^{5, 6, 7, 8}. Clinically-diagnosed cases included suspected cases with pneumonia as indicated by chest radiography, but without virological confirmation of infection⁶. The "clinical" definition was only used for one week in Hubei province as laboratory testing capacity was insufficient, and led to a large number of clinical cases to be isolated and treated without delay. These clinically-diagnosed cases were included in our study, recognizing the value of a clinical definition at the peak of a pandemic and in the context of limited laboratory testing capacity. The laboratory-confirmed cases include mild-to-critical cases, while the clinically-diagnosed cases include moderateto-critical cases. Definitions are presented in detail in Supplementary information file 1. **Data source** COVID-19 cases Our study aimed to account for underdiagnosis associated with the sensitivity of

laboratory assays, which is strongly dependent on the time lag between symptom

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

onset and diagnostic test¹². The distribution of lags varied at different phases of the epidemic in Wuhan due to laboratory testing capacity⁴. Accordingly, the daily number of COVID-19 cases by symptom onset date was preferred to the aggregated cumulative data. We obtained the following data: The daily number of laboratory-confirmed cases based on date of symptom onset in Wuhan extracted from a study which included 32,583 laboratory-confirmed COVID-19 cases as of March 8 (D1), and 17,365 clinically-diagnosed COVID-19 cases during February 9-19 (D2)⁴. The daily number of laboratory-confirmed cases in Wuhan based on reporting date on March 9-April 3 were extracted from the Hubei Health Commission (D3).³ The total number of COVID-19 deaths in Wuhan as of April 24 was obtained from the Hubei Health Commission $(D4)^3$. To correct the late reporting, omissions and mis-reporting of COVID-19 cases due to the healthcare capacity being overwhelmed during the outbreak, Wuhan Authorities conducted a comprehensive and systematic verification of reported COVID-19 cases between late March and middle April. A total of 325 laboratory-confirmed cases (D5) and 1,290 deaths (D6) were added on April 17^3 . The number of COVID-19 cases stratified by age and clinical category was obtained from the above sources data D1 and D2, while the age profile of fatal cases was obtained from the China CDC Weekly report^{4, 51}.

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

All of these datasets were registered through a surveillance system, which was launched to record information on COVID-19 cases in China at the start of the outbreak in late December 2019 in Wuhan⁹. These data were collected from passive surveillance, and active door-to-door and individual-to-individual screenings for fever. The active screening was implemented twice in Wuhan on a daily basis from January 24-February 10, and February 17-19^{10, 11}. A total of 16,781 laboratoryconfirmed cases were identified through active screening (D7, Details shown in Supplementary information file $2)^{10, 11}$. Sensitivity of RT-PCR A study retrospectively analyzed the RT-PCR assays of 301 patients with 1,113 specimens in Wuhan, and found that RT-PCR sensitivity varied at different phases of the epidemic due to the difference of interval between symptom onset and laboratory testing (P_{se}) (Supplementary information file 9). The sensitivity of RT-PCR assays was highest (97.9%) at an interval of <7 days¹². Health seeking behavior surveys A population-based telephone and online survey was conducted to understand the health seeking behaviors of patients suffering from acute respiratory infections (i.e.,

COVID-19 in Wuhan. Of patients with acute respiratory infections, 35.4% (95%CI

fever with any symptoms of cough, and/or sore throat) during the epidemic of

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

28.4%-43.9%) sought medical care, by adjusting for the age structure of Wuhan population. Children had a higher probability of medical attendance than adults $(P_{med,care})^{13}$. Other datasets A total of 10.7 million persons lived in Wuhan during the epidemic⁵². The age profile of the Wuhan population was obtained from the China Statistic Yearbook⁵³. To compare the burden of COVID-19 to baseline activity of acute respiratory infections, we obtained refence historical data on ILI surveillance in Hubei province and SARI surveillance in Jingzhou city, Hubei province^{14, 17, 21}. Additionally, we collected the annual number of consultations in pediatric and internal medicine departments in Hubei, and the national number of pneumonia hospitalization rates from the Chinese Health Statistics Yearbook⁵⁴. All these data were collected from publicly available sources and did not contain any personal identifiable information. Summary of data were presented in Supplementary information file 10. Statistical analysis Fig. 1 described the metrics we estimated, data flow, data analysis procedure and assumptions in the baseline analyses. All analyses were performed in R version $3.6.3^{55}$.

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

Reported COVID-19 cases in Wuhan In the baseline analysis, we considered COVID-19 cases in Wuhan as those with laboratory-confirmation or with a clinical diagnosis (for the brief period where the clinical definition was in place) and tabulated data by symptom onset date. The interval between symptom onset and diagnosis was obtained from data D1⁴. Then, we randomly simulated 10,000 draws from a gamma distribution representing these time intervals to estimate onset dates for laboratory-confirmed cases reported between March 9-April 3 (data D3), and added laboratory-confirmed cases (data D5). This allowed us to impute onset dates for cases that did not have this information. Medical consultations All cases from passive surveillance were considered as medical attendance (data D1+D3+D5, and D2). In the baseline analysis, we assumed that a proportion of mild cases, and all moderate-to-critical cases captured by active screenings in the community (data D7) would eventually seek medical care given that the health system was not overwhelmed (Assumption 1). The health seeking behavior of mild cases was assumed to be the same as aforementioned patients with acute respiratory infections during the COVID-19 epidemic $(P_{med,care})^{13}$. Hence, to estimate medically attended cases, we only excluded a proportion of $(1-P_{med,care})$ mild cases identified by community screening from the total reported COVID-19 cases. Moreover, the number

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

of laboratory-confirmed cases from official reports (data D1+D3+D5, and D7) was divided by the sensitivity of RT-PCR (P_{se}) to account for underdiagnoses. Symptomatic cases In the baseline analysis, we assumed the cases from surveillance system (data D1+D3+D5, and D2) had the same health seeking behavior as those captured by active screenings in the community (data D7) given that the health system was not overwhelmed (Assumption 1). Accordingly, the number of mild symptomatic cases was estimated by dividing reported mild COVID-19 cases by the probability of seeking medical care, conditionally on self-reported acute respiratory infection ¹³. Adjustment of sensitivity of RT-PCR was considered as well. Hospitalized cases Moderate-to-critical COVID-19 cases had radiographic evidence of pneumonia, while mild cases were defined as those without radiographic evidence of pneumonia^{5, 6, 7, 8}. Chest x-ray confirmed pneumonia is a threshold for hospital admissions in China. Accordingly, in our study, estimates for SARS-CoV-2 related hospitalizations excluded patients defined as mild cases in the baseline analysis. (Assumption 2) In above analyses, to account for the uncertainty of two parameters (RT-PCR sensitivity and probability of seeking medical care), we conducted a Monte Carlo

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

Simulation by drawing 10,000 samples on the basis of Binomial distributions. We generated 10,000 estimates for the number of COVID-19 cases, based on which we calculated the median, and 95% CIs (the 2.5th and 97.5th percentiles) for the outcomes of interest in this study. Additionally, below sensitivity analyses were conducted: in scenario i) for above Assumptions 1) and 2), we assumed moderate cases had the same health seeking behavior as mild cases, i.e., only a proportion of moderate cases sought medical assistance ($P_{med.care}$); and in scenario ii) we excluded clinically-diagnosed cases. Chisquare tests were used to compare the estimates of baseline and sensitivity analyses. Two-sided P values <0.05 were considered to indicate statistical significance. Disease burden We used the number of ILI consultations, and the number of SARI/pneumonia hospitalizations in the absence of COVID-19 outbreak as a reference to estimate COVID-19 related ILI medical consultations, and COVID-19 associated SARI/pneumonia hospitalization rate. Estimation of the number of ILI cases and SARI/pneumonia hospitalizations during the periods are shown in Supplementary Information file 11-14.

publication.

Moreover, for comparison with historical outbreaks, we conducted a narrative review on estimates of disease burden and clinical severity for the 1918 and 2009 influenza pandemics, as well as seasonal influenza in China and USA (Summary of studies shown in Supplementary Information file 4-5). The age profile of COVID-19 cases was obtained from *data D1*⁴, in which COVID-19 cases were broken down into 20-year age categories. We could not generate disease burden and clinical severity estimates for influenza using the same age stratification because numerators and denominators were not available from the literatures.

Role of the funding source

The funder of the study had no role in study design, data collection, data analysis, data

interpretation, or writing of the report. The corresponding author had full access to all

the data in the study and had final responsibility for the decision to submit for

perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

References

613

- 1. Johns Hopkins University. Coronavirus (COVID-19) Information and Updates.
- 615 https://www.coronavirustraining.org/live-map (accessed July 26 2020).
- 616 2. Centers for Disease Control and Prevention. Past Pandemics.
- 617 https://www.cdc.gov/flu/pandemic-resources/basics/past-pandemics.html (accessed 618 https://www.cdc.gov/flu/pandemics-pandemi
- Health Commission of Hubei Province. Daily report on epidemic situation of COVID-19 in Hubei province. (In Chinese).
- 621 http://wjw.hubei.gov.cn/bmdt/ztzl/fkxxgzbdgrfyyq/xxfb/index.shtml (accessed July 22 2020).
- 4. Pan A., *et al.* Association of Public Health Interventions With the Epidemiology of the COVID-19 Outbreak in Wuhan, China. *JAMA* **323**, 1915-1923 (2020).
- 5. Zhang J., *et al.* Evolving epidemiology and transmission dynamics of novel coronavirus disease 2019 outside Hubei Province in China: a descriptive and modeling study. *Lancet Infect. Dis.* **20**, 793-802 (2020).
- 628 6. National Health Commission of China. The diagnosis and treatment scheme of novel coronavirus diseases 2019 (Trial version 5th).
- 630 http://www.gov.cn/zhengce/zhengceku/2020-02/05/content_5474791.htm (accessed 631 February 25 2020).
- National Health Commission of China. The diagnosis and treatment scheme of novel coronavirus diseases 2019 (Trial version 6th).
- http://www.gov.cn/zhengce/zhengceku/2020-02/19/content_5480948.htm (accessed February 25 2020).
- 8. National Health Commission of China. The diagnosis and treatment scheme of novel coronavirus diseases 2019 (Trial version 7th).
- 638 http://www.gov.cn/zhengce/zhengceku/2020-02/19/content_5480948.htm (accessed February 25 2020).
- 640 9. Chinese Center for Disease Control and Prevention. Epidemic update and risk assessment of 2019 Novel Coronavirus. 2020. (In Chinese).
- 642 http://www.chinacdc.cn/yyrdgz/202001/P020200128523354919292.pdf (accessed January 31 2020).
- The State Council of the People's Republic of China. Announcement of Wuhan
 Headquarters for the Control and Treatment of Novel Pneumonia (No. 7) (In Chinese)
- 646 http://www.gov.cn/xinwen/2020-01/24/content_5472017.htm (accessed January 24 2020).
- 648 11. China Central Television. Report on results of 3-day screening in each district of Wuhan. (In Chinese).
- http://news.cctv.com/2020/02/20/ARTIfdQ2kV0eRTE4rgX2Aa3D200220.shtml (accessed February 20 2020).
- Xiao A., Tong Y., Gao C., Zhu L., Zhang Y., Zhang S. Dynamic Profile of RT-PCR Findings
 from 301 COVID-19 Patients in Wuhan, China: A Descriptive Study. *J. Clin. Virol.*, 104346

perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 654 (2020).
- Yang J., et al. Health seeking behaviors of patients with acute respiratory infections
- during the outbreak of novel coronavirus disease 2019 in Wuhan, China. *medRxiv*,
- https://doi.org/10.1101/2020.1105.1105.20091553 (2020).
- Feng L., et al. Burden of influenza-associated outpatient influenza-like illness
- consultations in China, 2006-2015: A population-based study. *Influenza Other Respir.*
- 660 *Viruses* **14**, 162-172 (2020).
- 661 15. Fowlkes A., et al. Incidence of medically attended influenza during pandemic and post-
- pandemic seasons through the Influenza Incidence Surveillance Project, 2009 13. Lancet
- 663 Respir. Med. 3, 709-718 (2015).
- Shrestha S. S., et al. Estimating the burden of 2009 pandemic influenza A (H1N1) in the
- United States (April 2009-April 2010). *Clin. Infect. Dis.* **52 Suppl 1**, S75-82 (2011).
- 666 17. Yu H., et al. The substantial hospitalization burden of influenza in central China:
- surveillance for severe, acute respiratory infection, and influenza viruses, 2010-2012.
- 668 Influenza Other Respir. Viruses 8, 53-65 (2014).
- Palekar R. S., et al. Burden of influenza-associated respiratory hospitalizations in the
- Americas, 2010-2015. *PloS One* **14**, e0221479 (2019).
- Reed C., et al. Estimating influenza disease burden from population-based surveillance
- data in the United States. *PloS One* **10**, e0118369 (2015).
- Dawood F. S., et al. Estimated global mortality associated with the first 12 months of
- 2009 pandemic influenza A H1N1 virus circulation: a modelling study. *Lancet Infect. Dis.*
- 675 **12**, 687-695 (2012).
- 676 21. Li L., et al. Influenza-associated excess respiratory mortality in China, 2010-15: a
- 677 population-based study. *Lancet Public Health* **4**, e473-e481 (2019).
- 678 22. Iuliano A. D., et al. Estimates of global seasonal influenza-associated respiratory
- 679 mortality: a modelling study. *Lancet.* **391**, 1285-1300 (2018).
- Frost W. H. The Epidemiology of Influenza. *Public Health Rep.* **34**, 1823-1836 (1919).
- Mamelund S. E., Haneberg B., Mjaaland S. A Missed Summer Wave of the 1918-1919
- Influenza Pandemic: Evidence From Household Surveys in the United States and
- Norway. Open Forum Infect. Dis. 3, ofw040 (2016).
- Presanis A. M., et al. The severity of pandemic H1N1 influenza in the United States, from
- April to July 2009: a Bayesian analysis. *PLoS Med.* **6**, e1000207 (2009).
- Wong J. Y., et al. Hospitalization Fatality Risk of Influenza A(H1N1)pdm09: A Systematic
- Review and Meta-Analysis. *Am. J. Epidemiol.* **182**, 294-301 (2015).
- Stokes E. K., et al. Coronavirus Disease 2019 Case Surveillance United States, January
- 689 22-May 30, 2020. *MMWR* **69**, 759-765 (2020).
- 690 28. Bignami S., Assche A. V. Assessing the burden of COVID-19 in Canada. *medRxiv*,
- 691 https://doi.org/10.1101/2020.1106.1114.20130815 (2020).
- 692 29. Gard S., et al. Hospitalization Rates and Characteristics of Patients Hospitalized with
- Laboratory-Confirmed Coronavirus Disease 2019 COVID-NET, 14 States, March 1–30,
- 694 2020. *MMWR* **69**, 458–464 (2020).
- 695 30. Lewnard J. A., et al. Incidence, clinical outcomes, and transmission dynamics of

perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

- hospitalized 2019 coronavirus disease among 9,596,321 individuals residing in California and Washington, United States: a prospective cohort study. *BMJ* **369**, m1923 (2020).
- WHO-China Joint Mission. Report of the WHO-China Joint Mission on Coronavirus
 Disease 2019 (COVID-19). https://www.chinadaily.com.cn/pdf/2020/who-china-joint-mission-on-covid-19-final-report.pdf (accessed March 19 2020).
- Zheng L. Analysis and suggestion on the factors leading to the difficulty in the
 construction of hierarchical diagnosis system. (In Chinese). *Chinese Health Econ* 38, 12-15 (2019).
- 704 33. New York City Department of Health and Mental Hygiene (DOHMH) COVID-19
 705 Response Team. Preliminary Estimate of Excess Mortality During the COVID-19
 706 Outbreak New York City, March 11–May 2, 2020. *MMWR* **69**, 603–605 (2020).
- 707 34. Weinberger D. M., *et al.* Estimation of Excess Deaths Associated With the COVID-19
 708 Pandemic in the United States, March to May 2020. *JAMA Intern. Med.*, doi:
 709 10.1001/jamainternmed.2020.3391 (2020).
- 710 35. Wu J. T., *et al.* Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. *Nat. Med.* **26**, 506-510 (2020).
- 712 36. Tian H., *et al.* An investigation of transmission control measures during the first 50 days of the COVID-19 epidemic in China. *Science* **368**, 638-642 (2020).
- 714 37. Wang D., *et al.* Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA* **323**, 1061-1069 (2020).
- 716 38. Zhou F., *et al.* Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet.* **395**, 1054-1062 (2020).
- 719 39. Henrik S., *et al.* Estimating the burden of SARS-CoV-2 in France. *Science* **369**, 208-211 720 (2020).
- 721 40. Yu J., *et al.* Respiratory Syncytial Virus Seasonality, Beijing, China, 2007-2015. *Emerg.* 722 *Infect. Dis.* 25, 1127-1135 (2019).
- 723 41. Zhang Z., *et al.* Genetic variability of respiratory syncytial viruses (RSV) prevalent in Southwestern China from 2006 to 2009: emergence of subgroup B and A RSV as dominant strains. *J. Clin. Microbiol.* **48**, 1201-1207 (2010).
- Sheikhzadeh E., Eissa S., Ismail A., Zourob M. Diagnostic techniques for COVID-19 and new developments. *Talanta* **220**, 121392 (2020).
- 728 43. Corman V. M., *et al.* Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-729 PCR. *Euro. Surveill.* **25**, (2020).
- He J., *et al.* Diagnostic performance between CT and initial real-time RT-PCR for clinically suspected 2019 coronavirus disease (COVID-19) patients outside Wuhan,
- 732 China. *Respir. Med.* **168**, 105980 (2020).
- 733 45. Bordi L., *et al.* Rapid and sensitive detection of SARS-CoV-2 RNA using the Simplexa[™] 734 COVID-19 direct assay. *J. Clin. Virol.* **128**, 104416 (2020).
- 46. Lai S., *et al.* Effect of non-pharmaceutical interventions to contain COVID-19 in China.

 Nature, doi: 10.1038/s41586-41020-42293-x (2020).
- 737 47. Leung K., Wu J. T., Liu D., Leung G. M. First-wave COVID-19 transmissibility and severity

738		in China outside Hubei after control measures, and second-wave scenario planning: a
739		modelling impact assessment. Lancet. 395, 1382-1393 (2020).
740	48.	Chen S., et al. Fangcang shelter hospitals: a novel concept for responding to public
741		health emergencies. Lancet. 395, 1305-1314 (2020).
742	49.	The State Council of the People's Republic of China. Press Conference of the Joint
743		Prevention and Control Mechanism of the State Council. (In Chinese).
744		http://www.gov.cn/xinwen/gwylflkjz48/index.htm (accessed March 8 2020).
745	50.	Li Z., et al. Active case finding with case management: the key to tackling the COVID-19
746		pandemic. <i>Lancet.</i> 396 , 63-70 (2020).
747	51.	The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The
748		Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases
749		(COVID-19) — China, 2020. <i>China CDC Weekly</i> 2 , 113-122 (2020).
750	52.	Health Commission of Hubei Province. The 20th press conference on prevention and
751		control of pneumonia caused by novel coronavirus. (In Chinese).
752		http://wjw.hubei.gov.cn/fbjd/dtyw/202002/t20200211_2023793.shtml (accessed
753		February 11 2020).
754	53.	National Bureau of Statistics. China Statistic Yearbook. http://www.stats.gov.cn/tjsj./ndsj/
755		(accessed March 3 2020).
756	54.	China Health Commission. Chinese Health Statistical Yearbook. China Peking Union
757		Medical College Press. (In Chinese).
758		http://navi.cnki.net/KNavi/YearbookDetail?pcode=CYFD&pykm=YSIFE&bh= (accessed
759		March 11 2020).
760	55.	The R Project for Statistical Computing. https://www.r-project.org/ (accessed March 18
761		2020).
762		

764

765

766

767

768

769

770

771

772

773

774

775

776


777

778


779


780

Acknowledgments The study was supported by grants from the National Science Fund for Distinguished Young Scholars (No. 81525023), National Science and Technology Major Project of China (No. 2018ZX10201001-010, No. 2018ZX10713001-007, No. 2017ZX10103009-005). **Author Contributions** H.Y. conceived, designed and supervised the study. J.Y., X.C., X.D., Z.C., H.G., H.Y., Q.W., H.S. and S.L. participated in data collection. J.Y., X.C., X.D., Z.C., and H.G. analyzed the data, and prepared the tables and figures. J.Y. prepared the first draft of the manuscript. S.L., M.A., C.V. and H.Y. commented on the data and its interpretation, revised the content critically. All authors contributed to review and revision and approved the final manuscript as submitted and agree to be accountable for all aspects of the work. **Declaration of interests** H.Y. has received research funding from Sanofi Pasteur, GlaxoSmithKline, Yichang HEC Changjiang Pharmaceutical Company, and Shanghai Roche Pharmaceutical



- 781 Company. None of those research funding is related to COVID-19. All other authors 782 report no competing interests. 783 784 **Additional information** Supplementary Information is available for this paper. 785
- 786 Correspondence and requests for materials should be addressed to J.Y., and H.Y.





Assumptions:

1) In the baseline analysis, it was assumed that a proportion of mild cases, and all moderate-to-critical cases captured by universal screenings in the community would eventually seek medical care given that the health system was not overwhelmed. And it was assumed that the cases from surveillance system had the same health seeking behavior as them;

2) In the baseline analysis, all moderate/severe/critical COVID-19 cases require hospitalization, while mild cases do not.

